Entry Point Capital, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
A detailed history of Entry Point Capital, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 630 shares of REGN stock, worth $350,626. This represents 0.18% of its overall portfolio holdings.
Number of Shares
630
Previous 653
3.52%
Holding current value
$350,626
Previous $414,000
20.29%
% of portfolio
0.18%
Previous 0.2%
Shares
4 transactions
Others Institutions Holding REGN
# of Institutions
1,398Shares Held
85.3MCall Options Held
1.39MPut Options Held
1.42M-
Vanguard Group Inc Valley Forge, PA9.42MShares$5.24 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.7 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.15 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.67 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.17MShares$1.76 Billion0.3% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $59.7B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...